Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third View: Examining the recent data from the PIONEER Trial of Blueprint's AYVAKIT (avapritinib) in treating patients with Indolent Systemic Mastocytosis

Ticker(s): BPMC

Who's the expert?

Institution: Charité – Universitätsmedizin Berlin

Assistant Professor, Head of the allergy inpatient care unit and the mastocytosis outpatient clinic at the Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin.
Treats approximately 350 patients with Indolent Systemic Mastocytosis.
Research focuses on the biology of mast cells and the pathophysiology of mast cell driven diseases; has participated in over 30 randomized clinical controlled trials.

Interview Goal

This conversation will focus on Blueprint Medicines' Ayvakit (avapritinib) in treating indolent systemic mastocytosis. We'll take a deeper look at the results from the PIONEER trial presented at the 2023 AAAAI Annual Meeting.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.